LSTA.US Lisata Therapeutics Inc.

Healthcare Biotechnology USA Stocks
1.09 USD
Close of Nov 16, 2026
0.9604 5.07
Market cap
USD 11.8M
P/E
-
P/B
1.63x
ROE
-247.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is LSTA.US undervalued?

Graham number

The Graham number of Lisata Therapeutics Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Lisata Therapeutics Inc. fundamental analysis

No fundamental analysis for Lisata Therapeutics Inc. yet.

Lisata Therapeutics Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Lisata Therapeutics Inc.

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of …

Full company profile